Cancer drug resistance: an evolving paradigm

Caitriona Holohan,Sandra Van Schaeybroeck,Daniel B. Longley,Patrick G. Johnston
DOI: https://doi.org/10.1038/nrc3599
IF: 78.5
2013-09-24
Nature Reviews Cancer
Abstract:Key PointsTumour resistance to chemotherapy and molecularly targeted therapies limits the effectiveness of current cancer therapies.Toxicity to normal tissues limits the amount of drug that can be systemically administered, and pharmacokinetic effects (absorption, distribution, metabolism and elimination (ADME)) limit the amount of drug that reaches the tumour.At the level of the tumour, various resistance mechanisms can operate, such as increased drug efflux, mutations of the drug target, DNA damage repair, activation of alternative signalling pathways and evasion of cell death.Tumour resistance can be intrinsic (that is, present before treatment), or acquired during treatment by various therapy-induced adaptive responses.Tumours are heterogeneous; therefore, resistance can also arise by positive selection of a drug-resistant tumour subpopulation.High-throughput screening techniques and systems biology approaches have the power to identify novel mechanisms of drug resistance and molecular signatures and genotypes that predict tumour response.Increasingly, predictive biomarkers will be used clinically to stratify patients to receive specific therapeutics.Improved understanding of the molecular basis of resistance will inevitably lead to the clinical assessment of rational drug combinations in selected patient populations.
oncology
What problem does this paper attempt to address?